General Health

General health issues, Medical conditions, Research and studies and more

Mental Health

Natural Medicine

Nutritional supplements, Herbs, Alternative medicine and more…

Wellness & Lifestyle

Nutrition, Diets, Healthy living, Detox, Exercise and Physical Fitness, Sports Fitness and more…

Women’s Health

Relationships, Pregnancy, Birth control, Menopause and more

Home » News

Heartening developments: Stanford expert discusses innovations in cardiac care

Article / Review by on February 2, 2012 – 8:39 pmNo Comments

Heartening developments: Stanford expert discusses innovations in cardiac care

Heartening developments: Stanford expert discusses innovations in cardiac care

February is American Heart Month, and to mark the occasion I sat down with Robert Robbins, MD, chair of the Department of Cardiothoracic Surgery (and director of the Stanford Cardiovascular Institute), to ask him about innovations in cardiac care and what the future holds.

My Q&A was recently posted on the Stanford Hospital & Clinics website, and I’ve included a few highlights below.

Robbins on minimally-invasive aortic valve replacement:

As part of a clinical trial, we’re doing some valve replacements transfemorally — that is, using a catheter to maneuver the new valve through blood vessels to the heart. Only one small incision to the femoral artery is needed, and the procedure generally takes little more than an hour. Recovery time is a few days.

On heart health and the human genome:

Much of the work in this area is being done at Stanford, where we have a lot of strength not only in mapping DNA but also interpreting the massive amount of data it produces. Our researchers will be able to create algorithms and ways to manage and interpret this data. One day you’ll probably be able to walk into your doctor’s office and say, “Here’s my genetic code. What does it mean?”

Another great hope is to customize drug therapy to specific cardiovascular diseases, such as hypertension, based on your genetic profile. If your genes make certain proteins or enzymes that metabolize a certain class of drugs better than another class, then doctors could use this so-called pharmacogenomic approach to customize treatments.

On stem cells:

I think they hold huge promise, but we’re not ready yet to employ stem-cell therapies to treat end-stage heart failure. But I do believe our group here at Stanford, one of the world’s leaders in this area, will be the first to put embryonic stem cells into the human heart.

By John Sanford
Stanford University Medical Center


Photo by


* Stanford University Medical Center integrates research, medical education and patient care at its three institutions – Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital.

**  The above story is adapted from materials provided by Stanford University School of Medicine


More about Stanford University

Tags: , , , , , ,

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>